Actuate Therapeutics (NASDAQ:ACTU – Get Free Report) and Dogwood Therapeutics (NASDAQ:DWTX – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, valuation, risk, profitability and institutional ownership.
Analyst Recommendations
This is a summary of recent ratings and target prices for Actuate Therapeutics and Dogwood Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Actuate Therapeutics | 1 | 0 | 2 | 0 | 2.33 |
| Dogwood Therapeutics | 1 | 0 | 1 | 0 | 2.00 |
Actuate Therapeutics currently has a consensus target price of $17.50, suggesting a potential upside of 489.23%. Dogwood Therapeutics has a consensus target price of $12.00, suggesting a potential upside of 610.06%. Given Dogwood Therapeutics’ higher possible upside, analysts plainly believe Dogwood Therapeutics is more favorable than Actuate Therapeutics.
Risk and Volatility
Valuation and Earnings
This table compares Actuate Therapeutics and Dogwood Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Actuate Therapeutics | N/A | N/A | -$22.23 million | ($1.05) | -2.83 |
| Dogwood Therapeutics | N/A | N/A | -$34.26 million | ($18.90) | -0.09 |
Actuate Therapeutics is trading at a lower price-to-earnings ratio than Dogwood Therapeutics, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Actuate Therapeutics and Dogwood Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Actuate Therapeutics | N/A | -799.68% | -205.80% |
| Dogwood Therapeutics | N/A | -2,027.44% | -31.29% |
Institutional and Insider Ownership
9.1% of Dogwood Therapeutics shares are held by institutional investors. 58.0% of Actuate Therapeutics shares are held by company insiders. Comparatively, 0.2% of Dogwood Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Summary
Actuate Therapeutics beats Dogwood Therapeutics on 6 of the 11 factors compared between the two stocks.
About Actuate Therapeutics
Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company’s lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. The company was incorporated in 2015 and is based in Fort Worth, Texas.
About Dogwood Therapeutics
Dogwood Therapeutics, Inc. is a development-stage biotechnology company, which engages in developing therapeutics for pain and fatigue illness. Its product includes Halneuron. It focuses on antiviral therapies IMC-1 and IMC-2 to treat diseases associated with a viral triggered abnormal immune response such as Long-COVID and fibromyalgia. The company was founded on February 28, 2012 is headquartered in Alpharetta, GA.
Receive News & Ratings for Actuate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actuate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
